Intravitreal brolucizumab is superior to panretinal laser photocoagulation in preserving visual acuity for patients with proliferative diabetic retinopathy, clinical trial data show.
In the treatment of glaucoma, the ability of continuous-wave (CW) transscleral laser photocoagulation (TSCPC) to lower intraocular pressure (IOP) must be weighed against its established risks.
This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye and improvements in restoring vision. In 1999, I defined ...
Please provide your email address to receive an email when new articles are posted on . The phase 3 BUTTERFLEYE trial compared aflibercept vs. laser photocoagulation in infants with retinopathy of ...
The phase 3 CONDOR trial found brolucizumab superior to panretinal laser photocoagulation for proliferative diabetic retinopathy, offering better vision outcomes and disease regression. The anti-VEGF ...
Changes in Choroidal Thickness Following Panretinal Photocoagulation: A Retrospective Study from Al Qassim, Saudi Arabia.
The BUTTERFLEYE trial sought to determine if aflibercept, an anti–vascular endothelial growth factor (anti-VEGF) therapy, was equivalent to laser photocoagulation, the gold standard to treat ...
Neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) can cause substantial disease burden for patients. Several organizations have published clinical guidelines on ...
Why did a 38-year-old woman with neurofibromatosis type 1 (NF1) develop choroidal Yasunari nodules in both eyes? That's what Danish clinicians had to figure out when the patient presented for a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results